Page last updated: 2024-12-08
tabernanthine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
tabernanthine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6326116 |
SCHEMBL ID | 3844372 |
MeSH ID | M0088647 |
Synonyms (12)
Synonym |
---|
83-94-3 |
tabernanthine |
tv52i1s16d , |
unii-tv52i1s16d |
13-methoxyibogamine |
tabernanthine [mi] |
tabernanthin |
ibogamine, 13-methoxy- |
SCHEMBL3844372 |
(1r,15r,17s,18s)-17-ethyl-6-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene |
DTXSID50878514 |
AKOS040762389 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 9 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |